

CS/NSE&BSE/BM/2019-20
March 23, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting


.....

With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 23rd March, 2020, has taken on record and approved the following matter(s).

- 1) Approved among other matters, the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) and Policy on determination of legitimate purpose in pursuance to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. The code is effective from March 9, 2020 and uploaded on our company's website and
- 2) Approved the repositioning of Suven Pharma, Inc. in USA (engaged in CRAMS related business), the wholly owned subsidiary of Suven Life Sciences Ltd to Suven Pharmaceuticals Ltd, post demerger subject to necessary approvals, if any.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited